Hologic (HOLX) Stock Forecast & Price Target

$57.28 -0.92 (-1.58%)

Closing price 04:00 PM Eastern

Extended Trading

$55.75 -1.53 (-2.67%)

As of 07:31 PM Eastern

Hologic - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 17 Analyst Ratings

Sell
0

Hold
11

Buy
6

Based on 17 Wall Street analysts who have issued ratings for Hologic in the last 12 months, the stock has a consensus rating of "Hold." Out of the 17 analysts, 11 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for HOLX.

Consensus Price Target

$84.62
47.72% Upside

According to the 17 analysts' twelve-month price targets for Hologic, the average price target is $84.62. The highest price target for HOLX is $95.00, while the lowest price target for HOLX is $70.00. The average price target represents a forecasted upside of 47.72% from the current price of $57.28.

Get the Latest News and Ratings for HOLX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hologic and its competitors.

HOLX Analyst Ratings Over Time

Type	Current Forecast 5/1/24 to 5/1/25	1 Month Ago 4/1/24 to 4/1/25	3 Months Ago 2/1/24 to 1/31/25	1 Year Ago 5/2/23 to 5/1/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	8 Buy rating(s)	4 Buy rating(s)
Hold	11 Hold rating(s)	11 Hold rating(s)	7 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$84.62	$84.62	$88.92	$87.00
Forecasted Upside	47.72% Upside	37.85% Upside	23.26% Upside	14.05% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Hold

HOLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HOLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Hologic Stock vs. The Competition

Type	Hologic	Medical Companies	S&P 500
Consensus Rating Score	2.41	2.82	2.54
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	47.72% Upside	3,372.49% Upside	19.82% Upside
News Sentiment Rating	Positive News See Recent HOLX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/4/2025	Citigroup 2 of 5 stars	P. Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$80.00 ➝ $70.00	+11.62%
3/3/2025	Argus 3 of 5 stars	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
2/6/2025	Leerink Partnrs 1 of 5 stars	P. Souda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
2/6/2025	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Cooper Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$95.00 ➝ $90.00	+36.28%
2/6/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Conor McNamara Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Perform ➝ Sector Perform	$88.00 ➝ $85.00	+27.79%
2/6/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
2/6/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	In-Line ➝ In-Line	$76.00 ➝ $73.00	+10.09%
2/6/2025	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mason Carrico Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$84.00 ➝ $84.00	+24.56%
2/6/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Puneet Souda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$80.00 ➝ $75.00	+3.02%
2/3/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$90.00 ➝ $90.00	+24.76%
Get the Latest News and Ratings for HOLX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Hologic and its competitors with MarketBeat's FREE daily newsletter.
1/13/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tejas Savant Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$84.00 ➝ $82.00	+16.41%
12/13/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Schenkel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
12/10/2024	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Ty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
12/10/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$85.00	+12.15%
11/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$84.00 ➝ $90.00	+12.60%
11/5/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$90.00 ➝ $87.00	+8.85%
11/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$92.00 ➝ $94.00	+17.79%
8/1/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$94.00 ➝ $86.00	+8.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:53 PM ET.

Should I Buy Hologic Stock? HOLX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 29, 2025. Please send any questions or comments about these Hologic pros and cons to contact@marketbeat.com.

Hologic
Bull Case

Here are some ways that investors could benefit from investing in Hologic, Inc.:

Hologic, Inc. reported earnings per share of $1.03 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
The company has a solid net margin of 18.42%, suggesting efficient management and profitability, which can be attractive to investors looking for stable returns.
With a return on equity of 19.72%, Hologic, Inc. demonstrates effective use of shareholders' equity to generate profits, a key indicator of financial health.
Analysts forecast an earnings per share of 4.28 for the current fiscal year, indicating expected growth and potential for increased stock value.
The current stock price is around $84.62, which is close to the average target price set by analysts, suggesting that the stock may be fairly valued with potential for appreciation.

Hologic
Bear Case

Investors should be bearish about investing in Hologic, Inc. for these reasons:

Several analysts have downgraded their ratings on Hologic, Inc., with some moving from "buy" to "hold," indicating a cautious outlook on the stock's future performance.
Target prices have been reduced by multiple firms, with some analysts lowering their expectations significantly, which may reflect concerns about the company's growth prospects.
The average rating for Hologic, Inc. is currently "Hold," suggesting that many analysts do not see strong upside potential in the near term.
Market conditions and competition in the medical equipment sector can impact Hologic, Inc.'s performance, making it a riskier investment in a volatile market.
Recent downgrades from firms like Leerink Partners and Citigroup may indicate a shift in market sentiment, which could lead to downward pressure on the stock price.

HOLX Forecast - Frequently Asked Questions

: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Hologic is $84.62, with a high forecast of $95.00 and a low forecast of $70.00.
: 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 11 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" HOLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HOLX, but not buy additional shares or sell existing shares.
: According to analysts, Hologic's stock has a predicted upside of 47.72% based on their 12-month stock forecasts.
: Over the previous 90 days, Hologic's stock had 4 downgrades by analysts.
: Hologic has been rated by research analysts at Argus, Citigroup, Evercore ISI, Leerink Partners, Leerink Partnrs, Needham & Company LLC, Raymond James, Royal Bank of Canada, Stephens, and William Blair in the past 90 days.
: Analysts like Hologic less than other "medical" companies. The consensus rating for Hologic is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HOLX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:HOLX) was last updated on 5/1/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hologic (HOLX) Stock Forecast & Price Target